Major allergy and immunology organizations (including the American Academy of Allergy, Asthma & Immunology and the Canadian Society of Allergy and Clinical Immunology) state that IgG food testing is not validated for diagnosing food allergy or intolerance and that elevated IgG may simply reflect exposure or tolerance rather than a pathological reaction.

However, more recent research has examined IgG-guided elimination diets specifically in IBS. A 2025 study from Michigan Medicine found that participants following an IgG-based personalized elimination diet experienced greater reductions in abdominal pain compared with those on a sham diet, with stronger effects in IBS-C and mixed subtypes. A 2026 systematic scoping review of 13 studies (935 IBS patients) reported associations with improvements in gastrointestinal symptoms and quality of life, while noting significant methodological limitations, heterogeneity, and the need for higher-quality trials. Risk of overly restrictive diets is a recognized concern.

At Tri-Health these panels are used selectively, with clear patient education about limitations, and always paired with clinical judgment and supervised dietary trials rather than lifelong rigid avoidance.

Serum-specific IgE testing is a standard, evidence-based tool in allergy diagnosis when interpreted with clinical history. It does not replace oral food challenges when needed, but provides valuable risk stratification and guidance.

Strong and growing legitimacy. The 2026 AHA/ACC dyslipidemia guidance emphasizes earlier risk assessment and measurement of ApoB and lipoprotein(a). ApoB is recognized as a superior marker of atherogenic particle number compared with LDL-C in many contexts. Lipoprotein(a) is largely genetic; a one-time measurement is increasingly recommended for lifetime risk estimation. hs-CRP adds independent inflammatory risk information. NMR particle data can further refine risk when discordance exists between cholesterol content and particle number.

Targeted hormone testing has clear clinical value when guided by symptoms and history (e.g., PCOS diagnostic criteria, male hypogonadism evaluation with morning total/free testosterone + LH/FSH, thyroid antibody testing). However, routine comprehensive “shotgun” hormone panels for diagnosing menopause are generally not recommended by major societies (NAMS and others emphasize clinical diagnosis based on age and symptoms; hormone levels fluctuate and do not reliably guide therapy decisions in typical menopause). At Tri-Health, panels are selected based on specific clinical questions rather than ordered indiscriminately.

Measurement of vitamin D, B12, folate, iron studies, and magnesium is well-established in both conventional and integrative care. Homocysteine is a recognized marker linked to cardiovascular and neurological risk when elevated. hs-CRP is an accepted independent risk factor for cardiovascular events. These panels are particularly useful when symptoms, dietary patterns, or gastrointestinal issues raise suspicion of insufficiency or inflammation.

Highly legitimate and guideline-supported. Serologic testing for celiac disease has good sensitivity and specificity when properly ordered and interpreted, though biopsy remains the gold standard for confirmation in most cases.

Fasting insulin, HOMA-IR (derived), and oral glucose tolerance testing with insulin are widely used to detect insulin resistance earlier than glucose alone. Combining metabolic, inflammatory, and hormonal markers provides a more complete picture than isolated glucose or lipid testing and aligns with current understanding of cardiometabolic risk.

Blood, RBC, and urine metal testing is standard in occupational and environmental medicine for documented exposures. In integrative settings these panels are used more broadly; interpretation requires careful consideration of specimen type, timing, and clinical context, as results can be influenced by recent intake or excretion patterns.